GH Guardant Health, Inc.
Services-Medical Laboratories · Nasdaq · SEC CIK 1576280 · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY31.0%
TTM net income YoY9.0%
TTM EPS YoY16.8%
Revenue 3-yr CAGR25.5%
Net income 3-yr CAGR—
Margins
Gross margin60.8%
Operating margin-60.0%
Net margin-59.0%
FCF margin-37.2%
EBITDA margin-54.4%
Returns
ROE-4,584.5%
ROA-26.7%
ROIC (approx.)—
Asset turnover0.45x
Leverage & solvency
Liabilities / assets109.4%
Debt / equity—
Current ratio4.68x
Interest coverage-171.87x
Cash quality & payout
Operating cash flow / net income0.55x
Accruals ratio-12.0%
Payout ratio—
Capex / revenue4.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $360.98M | $334.98M | $301.67M | $281.27M | $265.20M | $232.09M | $203.47M | $201.81M |
| Cost of revenue | $124.82M | $115.95M | $104.92M | $99.49M | $93.59M | $81.20M | $74.72M | $77.59M |
| Gross profit | $236.15M | $219.03M | $196.75M | $181.77M | $171.61M | $150.88M | $128.75M | $124.22M |
| R&D expense | $100.84M | $96.53M | $91.04M | $98.26M | $89.96M | $87.45M | $88.52M | $93.54M |
| SG&A expense | $90.86M | $61.66M | $57.93M | $60.93M | $53.27M | $50.26M | $46.95M | $51.88M |
| Operating income | -$132.76M | -$129.12M | -$121.35M | -$120.81M | -$98.99M | -$106.41M | -$111.04M | -$125.97M |
| Interest expense | $1.34M | $1.35M | $1.35M | $1.18M | $943,000 | $983,000 | $791,000 | $645,000 |
| Pretax income | -$124.02M | -$119.96M | -$111.70M | -$130.22M | -$92.59M | -$99.86M | -$94.87M | -$110.29M |
| Income tax | $343,000 | $185,000 | $372,000 | -$1.73M | $136,000 | $38,000 | $290,000 | $716,000 |
| Net income | -$124.36M | -$120.14M | -$112.08M | -$128.49M | -$92.72M | -$99.90M | -$95.16M | -$111.01M |
| EBITDA | -$122.86M | -$119.82M | -$111.91M | -$110.75M | -$89.99M | -$96.81M | -$100.81M | -$115.51M |
| EPS (basic) | -0.93 | -0.90 | -0.85 | — | -0.74 | -0.80 | -0.77 | — |
| EPS (diluted) | -0.93 | -0.90 | -0.85 | — | -0.74 | -0.80 | -0.77 | — |
| Weighted avg. shares (diluted) | 134.42M | 132.87M | 131.27M | — | 124.81M | 124.11M | 123.87M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $1.03B | $1.05B | $989.29M | $378.20M | $580.01M | $629.14M | $698.57M | $629.75M |
| Short-term investments | $0 | $0 | $113.47M | $823.39M | $0 | $0 | $0 | $314.44M |
| Receivables | $186.55M | $144.25M | $137.40M | $137.85M | $115.58M | $130.25M | $115.43M | $110.25M |
| Inventory | $93.49M | $105.46M | $83.85M | $85.88M | $90.49M | $84.06M | $77.26M | $71.08M |
| Current assets | $1.34B | $1.36B | $1.37B | $1.47B | $828.88M | $883.43M | $927.03M | $1.06B |
| PP&E, net | $151.47M | $155.30M | $150.03M | $145.91M | $124.61M | $126.14M | $129.29M | $136.81M |
| Goodwill | $77.26M | $77.26M | $77.26M | $77.26M | $3.29M | $3.29M | $3.29M | $3.29M |
| Intangibles | $24.99M | $25.27M | $25.54M | $25.92M | $5.48M | $5.86M | $6.28M | $6.76M |
| Total assets | $1.89B | $1.91B | $1.92B | $2.01B | $1.28B | $1.33B | $1.34B | $1.49B |
| Current liabilities | $373.17M | $338.96M | $292.14M | $302.73M | $236.92M | $238.43M | $225.75M | $225.58M |
| Long-term debt | $1.50B | $1.50B | $1.50B | $1.50B | $1.11B | $1.12B | $1.12B | $1.14B |
| Total debt | $1.50B | $1.50B | $1.50B | $1.50B | $1.11B | $1.12B | $1.12B | $1.14B |
| Total liabilities | $2.16B | $2.14B | $2.10B | $2.11B | $1.63B | $1.64B | $1.60B | $1.63B |
| Shareholders' equity | -$275.90M | -$222.87M | -$181.07M | -$99.31M | -$354.47M | -$305.48M | -$250.79M | -$139.65M |
| Net debt | $475.56M | $449.47M | $514.18M | $1.13B | $534.58M | $486.38M | $417.77M | $512.79M |
| Shares outstanding | 134.72M | 133.61M | 131.51M | 130.64M | 125.01M | 124.48M | 123.65M | 123.99M |
| Cash flow statement | ||||||||
| Operating cash flow | -$23.71M | -$57.78M | -$65.62M | -$26.37M | -$35.41M | -$60.28M | -$62.69M | -$64.51M |
| Capital expenditure | $13.48M | $11.76M | $5.58M | $27.85M | $10.35M | $5.65M | $4.46M | $18.88M |
| Free cash flow | -$37.19M | -$69.54M | -$71.20M | -$54.22M | -$45.76M | -$65.93M | -$67.15M | -$83.39M |
| Investing cash flow | -$13.48M | $101.47M | $699.42M | -$905.07M | -$14.35M | -$10.65M | $302.86M | $10.53M |
| Financing cash flow | $15.01M | $23.01M | -$21.58M | $732.03M | $4.33M | $1.62M | -$66.85M | -$2.94M |
| Depreciation & amortization | $9.90M | $9.30M | $9.44M | $10.05M | $9.00M | $9.60M | $10.24M | $10.45M |
| Stock-based compensation | $62.44M | $57.73M | $47.61M | $43.19M | $42.81M | $42.46M | $37.76M | $36.37M |
| Share buybacks | $0 | $0 | $0 | $0 | $0 | $0 | $45.01M | $0 |
Free plan shows the latest 8 periods; Pro shows all 37 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.